Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Santarus

1996 FOUNDED
M&A STATUS
501-600 EMPLOYEES
M&A LATEST DEAL TYPE
$2.6B LATEST DEAL AMOUNT
Description

Provider of pharmaceutical products for the treatment of upper and lower gastrointestinal diseases and disorders. The company focus on the development and commercialization of next generation proton pump inhibitor, or PPI, products the most frequently prescribed drugs for the treatment of many upper gastrointestinal, or GI, diseases and disorders.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Primary Office
  • 3611 Valley Centre Drive
  • Suite 400
  • San Diego, CA 92130
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Santarus’s full profile, request a free trial.

Santarus Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 03-Jan-2014 $2.6B 00000 00.00 Completed Generating Revenue
7. Revolving Credit Line 01-Aug-2006 00000 Completed Generating Revenue
6. PIPE 00000 Completed Generating Revenue
5. IPO 01-Apr-2004 0000 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 19-May-2003 000.00 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 07-Mar-2001 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Jan-1999 $5.28M $5.34M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Dec-1996 $62K $62K 00000 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Santarus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 5,276,000 $0.000100 8% $1 $1 1x $1 5.08%
Series A 620,000 $0.000100 5% $0.1 $0.1 1x $0.1 0.6%
To view this company’s complete Cap Table, request access »

Santarus Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000000 ( 21-Dec-2011 000000000 00000 00 Pharmaceuticals
Covella Pharmaceuticals 10-Sep-2010 Merger/Acquisition 00000 Biotechnology 000000 000000
To view this company’s complete investment and acquisition history, request access »

Santarus Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
Advent Venture Partners Venture Capital Minority 000 0000 000000 0
CDIB BioScience Venture Management Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
Fog City Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Santarus Executive Team (16)

Name Title Board
Seat
Contact
Info
Gerald Proehl President & Chief Executive Officer
Debra Crawford Senior Vice President & Chief Financial Officer, Treasurer and Secretary
Carey Fox JD Senior Vice President & General Counsel
Mark Totoritis MD Senior Vice President, Clinical Research
Julie DeMeules Senior Vice President, Human Resources

4 Former Executives

You’re viewing 5 of 16 executives. Get the full list »

Santarus Board Members (8)

Name Representing Role Since Contact
Info
Alessandro Della Chà Self Board Member 000 0000
David Hale Self Chairman 000 0000
Kent Snyder Self Board Member 000 0000
Ted Love MD Self Board Member 000 0000

4 Former Board Members

You’re viewing 4 of 8 board members. Get the full list »